A service of StreetInsider.com
Ticker Symbol

Most Popular

AAPL 136.66
GOOG 828.64
MSFT 64.62
FB 135.44
BAC 24.23

Recently Added

STRL 9.32
LAYN 9.54
NOA 5.35
LL 17.39
WGL 83.28

Gaining Speed

BLBD 16.70
ATGFF 23.60
WGL 83.28
LAYN 9.54
STRL 9.32

ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS....

Read More




Get Alerted When News Hits On This Stock - FREE!